Real-World Validation of Arkangel AI, a Conversational Agent for Real-Time Evidence-Based #Medical Question Answering: #RCT #ClinicalTrial Date Submitted: Feb 17, 2026. Open Peer Review Period: Mar 11, 2026 - May 6, 2026.

Reminder>> Real-World Validation of Arkangel AI, a Conversational Agent for Real-Time Evidence-Based #Medical Question Answering: #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

Here's the third (and last!) entry in a series of blog posts on the #cdisc Dataset-JSON standard. This entry goes over the REST API component and potential issues with it.

Pushing for the future of #clinicaltrial #data (and related to the #pharmaverse and #rstats folks in #biomedicalresearch) […]

Reminder>> A Fully Remote Serious #Game for Cognitive Control Training in Major Depressive Disorder: A #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775 Background In Study 309/KEYNOTE-775 ( NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progression-free survival (PFS), overall survival (OS), and objective response r...

#Lenvatinib plus #pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775 jitc.bmj.com/content/14/2...

#clinicaltrial #endometrialcancer

@choosesjc.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Phase Ia/Ib #ClinicalTrial shows that mesenchymal stromal cell therapy safely improves liver function and exerts dose-dependent immunomodulation, suggesting a promising regenerative strategy in decompensated #Cirrhosis.

#STTT #OpenAccess: doi.org/10.1038/s413...

I drew Angel and Lee from Clinical Trial ...... I keep thinking about these two

#clinicaltrialgame #clinicaltrialfanart #leesmith #angelmartinez #clinicaltrial #art #sketch

Reminder>> Immersive 3D Simulation vs. Physical Models in Training Novices for Laser-based Endourological Procedures - #Research #Protocol for a #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

🚨 NOW ENROLLING 🚨 The #ELEGANT #clinicaltrial is studying whether #Orserdu works better than standard hormonal therapy for adults with ER-positive, HER2-negative #breastcancer with lymph node involvement who have taken hormonal therapy for 2–5 years.

Learn more: https://bit.ly/4aZK

A randomized #ClinicalTrial shows that #Allogeneic dental pulp stem cell injections enhance periodontal regeneration and improve clinical outcomes, thereby supporting a safe, minimally invasive stem-cell therapy for #Periodontitis. @pku1898.bsky.social

#STTT #OpenAccess: doi.org/10.1038/s413...

Strong Response Rate for Claseprubart in CIDP Supports Continuing to Controlled Phase of Trial Dianthus Therapeutics announced promising early results for claseprubart, a next-generation C1s inhibitor designed to treat CIDP.

Dianthus Therapeutics announced an early “go” decision for #Claseprubart for the treatment of chronic inflammatory demyelinating polyneuropathy (#CIDP).

Read here: https://bit.ly/4dfTZeI

#RareDisease #ClinicalTrial #CAPTIVATE

art of Lee and Angel side by side

Angel e o Lee

#clinicaltrial

The #clinicalTrial I've been participating in for a revolutionary new #cholera #vaccine has been published in #TheLancet, and the results are excellent.
www.thelancet.com/journals/laninf/article/...
I'm one of the data points in this article. 😉
The immunity […]

Clinical Trial Finds Sulthiame Reduces Breathing Pauses in Sleep Apnea Patients

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

#sleepapnea #sulthiame #clinicaltrial

View full AI summary:

wip

#clinicaltrial

Real-World Validation of Arkangel AI, a Conversational Agent for Real-Time Evidence-Based #Medical Question Answering: #RCT #ClinicalTrial Date Submitted: Feb 17, 2026. Open Peer Review Period: Mar 11, 2026 - May 6, 2026.

Real-World Validation of Arkangel AI, a Conversational Agent for Real-Time Evidence-Based #Medical Question Answering: #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

Clinical Efficacy Evaluation of Tuina Combined Medicated Oil in the Treatment of Nonspecific Low Back Pain: #Protocol for a #RCT #ClinicalTrial Background: Nonspecific low back pain (NSLBP) is a significant global public health concern that affects the health and well-being of individuals across different age groups, limiting their daily activities and reducing their quality of life. As Tuina (Chinese therapeutic massage) therapy and medicated oil are widely used in China, it is necessary to design a randomized clinical trial to assess the effectiveness of Tuina combined medicated oil (TNO) in treating NSLBP. Objective: This #Study aims to evaluate the efficacy and safety of Tuina therapy combined with medicated oil in treating NSLBP. Methods: One hundred participants will be enrolled and randomly allocated to either a TNO group (n=50) or a Tuina combined water group (n=50). Treatment will last for 4 weeks, with sessions 3 times a week, followed by a 4-week follow-up. The visual analog scale score is the primary outcome; secondary outcomes include the evaluation of treatment Japanese Orthopaedic Association scores, infrared thermography, muscle tension tests, and tenderness scores. All adverse reactions will be recorded. Results: The trial commenced in June 2023 and is expected to conclude in September 2025. In June 2025, key preliminary steps were completed, and the ethical review and clinical trial registration were concluded. Recruitment is proceeding as planned, with 100 participants enrolled to date. Data collection is underway, while formal data analysis has not yet commenced. Conclusions: The project’s purpose is to evaluate the effectiveness of TNO in alleviating pain and improving lumbar function in patients with NSLBP. Trial Registration: ChiCTR ChiCTR2300076144; https://www.chictr.org.cn/hvshowproject.html?id=247247 International Registered Report Identifier (IRRID): DERR1-10.2196/81887

JMIR Res Protocols: Clinical Efficacy Evaluation of Tuina Combined Medicated Oil in the Treatment of Nonspecific Low Back Pain: #Protocol for a #RCT #ClinicalTrial

Study suggests supplement may reproduce elements of fasting biology in older adults with elevated HbA1c – without dietary restriction.

vist.ly/4ujmv

#longevity #fastingmimetic #metabolichealth #agingresearch #supplements #healthspan #metabolism #clinicaltrial

A Fully Remote Serious #Game for Cognitive Control Training in Major Depressive Disorder: A #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

Immersive 3D Simulation vs. Physical Models in Training Novices for Laser-based Endourological Procedures - #Research #Protocol for a #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

More Angel <3
#clinicaltrial #clinicaltrialgame #clinicaltrialfanart #clinicaltrialrpg #fanart #art #angelmartinez

Reminder>> Effects of breathing exercises on #Pain, disability, range of motion and muscle endurance in #Patients with chronic low back #Pain, a #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

Impact of the Population Medicine Multimorbidity Intervention in Xishui County (POPMIX) on People at High Risk for Chronic Obstructive Pulmonary Disease Who Experience Mental Health Symptoms: #Protocol for the POPMIX-MH Cluster #RCT #ClinicalTrial Background: Chronic obstructive pulmonary disease (COPD) and mental health conditions represent intersecting public health challenges, especially in resource-limited rural China. Existing care models often neglect the psychosocial needs of populations at high risk for COPD, resulting in limited effectiveness of prevention and management strategies. This #Study evaluates an integrated intervention designed to improve both mental and physical health outcomes among high-COPD-risk individuals with mental health symptoms, using a population medicine framework. Objective: This #Study aims to evaluate the effect of an integrated, population medicine–based multimorbidity intervention package among high-COPD-risk individuals with mental health symptoms in Xishui County, Guizhou Province, China. Methods: We are conducting a 12-month, 2-arm cluster #RCT #ClinicalTrial across 26 townships in Xishui County, Guizhou, China. A total of 44,000 residents aged ≥35 years were screened using the Chronic Obstructive Pulmonary Disease Screening Questionnaire, identifying 10,000 individuals at high risk of COPD. Among them, 3807 individuals with Warwick-Edinburgh Mental Well-Being Scale scores below 45 were enrolled as participants. Intervention components include #Digital cognitive behavioral therapy–based mental health support, community screening, chronic disease management, patient education, #Digital follow-up, and team-based care. The primary outcomes are depressive symptoms (9-item Patient Health Questionnaire), anxiety symptoms (7-item General Anxiety Disorder), and mental well-being (Warwick-Edinburgh Mental Well-Being Scale). Secondary outcomes are control of chronic diseases, physiological and functional indicators such as lung function, health-related quality of life, mental and behavioral health, health care utilization, knowledge of COPD and asthma, productivity loss, and care cascade indicators for chronic conditions. Results: Data collection for the POPMIX-MH trial began in June 2024. Baseline, 3-month, and 6-month assessments have been completed, and the 12-month follow-up assessments are planned to be completed in March 2026. Conclusions: This #Study is the first to integrate psychological support, chronic disease management, and community-based screening into a single scalable intervention package targeting multimorbidity in China. It tests the feasibility of applying population medicine principles, emphasizing integrated, preventive, and population-level care, within primary care systems in low-resource settings. By targeting both mental and physical health, it redefines chronic care beyond traditional organ-specific approaches. Trial Registration: ClinicalTrials.gov NCT06458218; https://clinicaltrials.gov/ct2/show/NCT06458218

JMIR Res Protocols: Impact of the Population Medicine Multimorbidity Intervention in Xishui County (POPMIX) on People at High Risk for Chronic Obstructive Pulmonary Disease Who Experience Mental Health Symptoms: #Protocol for the POPMIX-MH Cluster #RCT #ClinicalTrial

#cs_aiw #eu #projects #ai #cancersurvivorship #cluster #mentalhealth #digitalhealth #patients #clinicaltrials #whitepaper #policymaking #healthcare #research #report #stakeholders | The Cancer Survivo... Cluster evolving .. Second White Paper due for imminent release. The Cancer Survivorship and AI for Well-being cluster (#CS_AIW) is a collaborative initiative that brought together several #EU-funded...

Second white paper due for immient release ..

linkedin.com/posts/cs-aiw...

cs-aiw.eu

#AI, #cancerresearch, #Horizon_EU, #cluster, #Clinicaltrial, #technology, #HorizonEurope

Pre-Screen Online: cloud.patientengagement.heliosclinical.com/covid19study
#COVID19Research #ClinicalTrial #HealthStudy

Effects of breathing exercises on #Pain, disability, range of motion and muscle endurance in #Patients with chronic low back #Pain, a #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis–Removing Therapy for Multiple Myeloma: #Protocol for a #RCT #ClinicalTrial on Epigenetic and Immune Modulation Background: Multiple myeloma (MM) is characterized by kidney deficiency, phlegm, and blood stasis as core findings, specifically in Traditional Chinese Medicine (TCM), and the kidney-tonifying, phlegm-resolving, and blood stasis–removing (KPR) method is a fundamental therapeutic approach for MM in TCM. Western medicine primarily focuses on targeted immunotherapy or chemotherapy for MM treatment, whereas TCM characterizes MM through distinct pathological patterns that directly correspond to immune microenvironment dysregulation. Emerging evidence implicates the PHD finger protein 19 (PHF19)/enhancer of zeste homolog 2 (EZH2)/trimethylated histone H3 at lysine 27 (H3K27me3) epigenetic axis in immune microenvironment dysregulation and MM progression. Notably, TCM “blood stasis” correlates with hypoxia-induced immune gene silencing in MM bone marrow, and KPR (a clinically validated TCM decoction with 16 herbs) acts on this axis via its active components that regulate EZH2 and epigenetic function, merging TCM syndrome differentiation with modern epigenetics. We have designed a #RCT #ClinicalTrial (RCT) to investigate the mechanism of action and safety of the KPR method in MM. Objective: This RCT aims to assess whether a KPR herbal formula combined with standard bortezomib-based therapy improves the immune microenvironment via the PHF19-EZH2-H3K27me3 epigenetic axis to restore immune function in MM, providing a mechanistic basis for integrating TCM into evidence-based oncology care in relapsed or refractory patients. Methods: This is a single-center, prospective RCT involving patients with MM. It has been designed to test the hypothesis that the KPR formula epigenetically regulates the PHF19-EZH2-H3K27me3 axis to improve the immune microenvironment. Patients are randomly assigned in a 1:1:1 ratio to 3 groups (blank control group, Western medicine control group, and integrated TCM and Western medicine treatment group). All patients undergo 12 weeks of treatment and a 6-month follow-up. The primary outcome is the CD3 T-cell ratio in bone marrow/peripheral blood, which is detected by flow cytometry. The secondary outcomes include quantified TCM syndrome scores, Western medicine efficacy evaluation criteria, complete blood count, bone marrow morphology, blood and urine immunoglobulin levels, quantitative M protein levels, free light chain levels, β2-microglobulin levels, and whole-body imaging findings. Statistical analysis involves linear mixed models for longitudinal data and Bonferroni correction to verify KPR’s immunomodulatory effects via the targeted epigenetic axis. Results: This #Study was funded in November 2023. Recruitment was initiated in March 2025 and is expected to be completed in February 2026. As of October 2025, 41 patients have been enrolled. Data collection is projected to end in October 2026. Data analysis has not yet been initiated, and the results are expected to be published in 2027. Conclusions: This unique mechanistic RCT evaluating a TCM formula targeting the PHF19-EZH2-H3K27me3 axis in patients with MM will establish a biomarker-driven framework for integrating TCM with immunotherapy, offering novel strategies for treatment-refractory patients. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000671; https://itmctr.ccebtcm.org.cn/mgt/project/view/4375050683463103813 and ITMCTR2025000449; https://itmctr.ccebtcm.org.cn/mgt/project/view/4779140633660123982 International Registered Report Identifier (IRRID): DERR1-10.2196/86322

JMIR Res Protocols: Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis–Removing Therapy for Multiple Myeloma: #Protocol for a #RCT #ClinicalTrial on Epigenetic and Immune Modulation

Travel to #Cincinnati for a paid research study? Find out more here: clinicalherostudies.com/cincystudy44... #healthy #clinicaltrial

Pfizer、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI） | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、

Pfizer's BREAKWATER Trial Cohort 3 Shows Significant PFS Improvement in First-Line BRAF V600E-Mutant mCRC

ファイザー、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI）

stellanews.life/technology/8...

#ColorectalCancer #Pfizer #BREAKWATER #BRAF #Oncology #ClinicalTrial

Pfizer、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI） | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、

Pfizer's BREAKWATER Trial Cohort 3 Shows Significant PFS Improvement in First-Line BRAF V600E-Mutant mCRC

ファイザー、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI）

stellanews.life/technology/8...

#ColorectalCancer #Pfizer #BREAKWATER #BRAF #Oncology #ClinicalTrial